Rick Pendergraft's Avatar
Rick Pendergraft
published in Blogs
Jun 22, 2020
Mixed Messages on Biotech Sector with Strong Fundamentals, but Overvalued Currently

Mixed Messages on Biotech Sector with Strong Fundamentals, but Overvalued Currently

The current health crisis has created a lot of buzz around the biotech sector as several companies from the sector are working on potential vaccines against the COVID-19 virus. That buzz has created somewhat of a mixed message for the sector as a whole. Many of the companies are overvalued at this time, but the fundamentals of many are really good.

I looked at the SPDR S&P Biotech ETF (NYSE: XBI) and its components. First, I looked at the chart of the ETF itself and saw the huge bounce off of the March low—moving from the $65 area to over $110 in approximately three months. As impressive as the move is, it is also troubling for someone like me that has a hard time buying stocks or ETFs when they are overbought.

After looking at the chart and the move the XBI has made, I started looking at the individual companies and their fundamental ratings along with the scorecard grades from Tickeron. What I found there was pretty impressive.

Of the 85 components in the XBI, 41 are rated as a “strong buy” and 17 are rated as a “buy”. There are seven “hold” ratings, eight “sell” ratings, and 10 “strong sell” ratings. There were also two that didn’t have a rating on the scorecard. I found it to be a really good sign for the long-term prospects of the sector with almost 70% of the ratings coming in at a buy or better. Keep in mind these ratings are strictly based on artificial intelligence, they aren’t the same thing as analysts’ ratings where human opinions are taken in to account.

The problem with the components is that so many are overvalued at this time. Of the 85 stocks in the fund, 45 are “overvalued”, 29 are “fairly valued”, and only 11 are “undervalued”.

The biotechnology industry involves genetic or protein engineering. The goal is to produce medicines or therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion dollar industry is heavily focused on research and development.  Companies are continuously attempting to come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide growth opportunities for the companies. However, discoveries must pass regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets.

Some of the most notable companies in the group are Amgen Inc. (NASDAQ:AMGN), Gilead Sciences, Inc. (NASDAQ:GILD), Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), Illumina Inc (NASDAQ:ILMN), Biogen Inc (NASDAQ:BIIB), Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), Moderna Inc (NASDAQ:MRNA), Incyte Corp. (NASDAQ:INCY), Exact Sciences Corp. (NASDAQ:EXAS), and Sarepta Therapeutics Inc (NASDAQ:SRPT).

Of those notable companies, only Amgen falls in to the undervalued category at this time. Exact Sciences is fairly valued and all the rest of those notable companies are in the overvalued category at this time.

What all of this suggest to me is that the long-term prospects for the XBI and the biotech sector as a whole are really good. But investors might want to wait for a pullback before jumping in.

One particular technical indicator that jumped out at me was the RSI indicator. Over the last three weeks or so, 36 of the stocks in the XBI have received a signal from this indicator and only four of those 36 were bullish signals with good odds of success. There was one bearish signal that didn’t have good odds of success, but there were 31 bearish signals where the odds of success were at 60% or better. 

Given all of this information, I can see making a bullish trade on the biotech sector if the stocks as a whole see a little pullback. If enough of the stocks go through a little downturn, it should reduce the number of stocks that are overvalued. Such a move would give investors a chance to enter a trade without buying when the indicators are in overbought territory.

Related Tickers: XBI
Sergey Savastiouk's Avatar
Sergey Savastiouk
published in Blogs
Mar 07, 2021
4 Tricks Hedge Funds Use to Get Ahead

4 Tricks Hedge Funds Use to Get Ahead

If the stock market were Major League Baseball, hedge funds and institutional investors would be the pros on championship teams while everyday self-directed investors (SDIs) are the benchwarmers in the minors.It’s how they get ahead, and it’s why 90% of SDIs lose money trying to play (invest and trade) in the major leagues. The 4 tricks we discuss below are rooted in one common theme: they all use Artificial Intelligence and algorithms to generate data and ideas.
John Jacques's Avatar
John Jacques
published in Blogs
Mar 22, 2018
A.I. Stock Market Predictions: Head & Shoulders

A.I. Stock Market Predictions: Head & Shoulders

Statistics for the Head-and-Shoulders Bottom Pattern The days where only hedge funds used algorithms to trade stocks are officially over. Now retail investors can use Artificial Intelligence (A.I.  Here’s an example of the algorithm in action: Late last year, Tickeron’s A.I.
Sergey Savastiouk's Avatar
Sergey Savastiouk
published in Blogs
Jul 10, 2020
3 Stocks to Buy if Coronavirus Second Wave Hits

3 Stocks to Buy if Coronavirus Second Wave Hits

By analyzing market trends from the first wave, you can predict behavior for the second. Technology stocks have performed at historic levels this year, but the market is severely overbought.To compensate for that, look at performance during Q1 and Q2, the height of global Covid shutdowns.
Edward Flores's Avatar
Edward Flores
published in Blogs
Feb 06, 2021
How to Become the Millionaire Next Door

How to Become the Millionaire Next Door

The Golden Gate Bridge is always a fixture of these walks too, one of man's most beautiful creations.  As we were walking, at one point she turned to me and said, "Man, I'll never have a million dollars."" My girlfriend is 27 years old and works as a graphic designer, making about $75,000 a year.
Alla Petriaieva's Avatar
Alla Petriaieva
published in Blogs
Feb 23, 2021
Is Ethereum’s Bomb about to Explode?

Is Ethereum’s Bomb about to Explode?

Ethereum’s software is set for an update in October.Until it is finished, participants in the Ethereum blockchain must determine how to delay the difficulty bomb – code that necessitates a steadily increasing amount of computer power to mine blocks and unlock rewards – that is already in place.
Sergey Savastiouk's Avatar
Sergey Savastiouk
published in Blogs
Aug 07, 2018
When Is the Next Recession Coming?

When Is the Next Recession Coming?

However, we also know that economists predicted 22 recessions out of 11 that took place since 1945. Are there real recession signs we should watch for?Indeed, the answer is yes, and here are a few very important ones: The first one is almost obvious and known to everyone – it is the Fed.
Abhoy Sarkar's Avatar
Abhoy Sarkar
published in Blogs
May 22, 2020
Central banks have been buying $2.4 billion in assets every hour for the past two months

Central banks have been buying $2.4 billion in assets every hour for the past two months

Some $17.8 billion has been poured into  bond markets over the past week, the biggest move in more than three months.Around $3.5 billion has been invested into gold, the second largest on record. 
Rick Pendergraft's Avatar
Rick Pendergraft
published in Blogs
Feb 07, 2021
Mid-January Short Interest Report Shows 8 Stocks with Good Fundamentals and High Short Interest
Sergey Savastiouk's Avatar
Sergey Savastiouk
published in Blogs
Mar 10, 2021
How to Start Trading Penny Stocks

How to Start Trading Penny Stocks

Penny stocks have long been marginalized within the professional investment community, oftentimes being painted with a broad brush of simply being “too risky.” Leonardo DiCaprio’s depiction of the penny stock peddling conman, Jordan Belfort, in the Wolf of Wall Street certainly didn’t help.Here are four reasons to start trading them now. Reason #1: Let’s State the Obvious -- Penny Stocks are Cheap A single share of Apple Inc. costs over $350.
Abhoy Sarkar's Avatar
Abhoy Sarkar
published in Blogs
May 08, 2020
US unemployment rate jumps to 14.7%, the highest in series history

US unemployment rate jumps to 14.7%, the highest in series history

The U.S. economy’s employment fell by -20.5 million in April. The coronavirus crisis led to unemployment rate soaring to 14.7% in the U.S, the highest rate in the Bureau of Labor Statistics-tracked series history that goes back to 1948. However, the figures were better compared to several economists'/analysts' forecasts of 22 million job losses and 16% unemployment rate.  Another unemployment measure that includes those who have stopped looking for work as well as those holding part-time jobs for economic reasons also touched an all-time high of 22.8%.